Table 2.

Effect of treatment on disease activity, lipid profile, adipokines, and hemodynamics. Values represent mean ± standard deviation.

Feature	Patient Group 1		Patient Group 2		Significance Between Drugs, p^†
Feature	Baseline, n = 15	Posttreatment, n = 15	Baseline, n = 15	Posttreatment, n = 15	Significance Between Drugs, p^†
TJC	11.0 ± 2.59	7.20 ± 1.61^*	11.13 ± 3.13	3.8 ± 1.32^*	< 0.001
SJC	6.73 ± 2.34	4.20 ± 1.78^*	6.06 ± 2.60	1.53 ± 0.83^*	< 0.001
VAS	54.66 ± 13.55	42.00 ± 10.82^*	56.0 ± 14.78	21 ± 6.86^*	< 0.001
ESR, mm/h	56.93 ± 20.81	43.60 ± 20.30^*	58.33 ± 22.02	26.73 ± 8.56^*	< 0.001
CRP, mg/l	33.06 ± 14.13	19.73 ± 10.84^*	31.46 ± 14.33	7.20 ± 3.09^*	< 0.001
DAS28	6.19 ± 0.82	5.27 ± 0.66^*	6.09 ± 0.88	3.9 ± 0.45^*	< 0.001
Morning stiffness, min	77.0 ± 35.79	59.33 ± 33.79^*	86.0 ± 44.80	19.33 ± 10.66^*	< 0.001
TC, mg/dl	224.66 ± 31.12	235.66 ± 30.93^**	228.13 ± 11.75	191.80 ± 12.77^*	< 0.001
TG, mg/dl	137.33 ± 47.31	137.13 ± 46.78	126.93 ± 31.97	96.60 ± 18.69^*	< 0.001
LDL-C, mg/dl	142.33 ± 24.41	140.40 ± 25.70	142.66 ± 24.33	120.26 ± 14.14^*	< 0.001
HDL-C, mg/dl	44.06 ± 9.12	51.73 ± 10.05^*	41.60 ± 10.85	60.07 ± 9.38^*	< 0.001
TC/HDL-C	5.31 ± 1.38	4.72 ± 1.11^*	5.75 ± 1.44	3.26 ± 0.48^*	< 0.001
LDL-C/HDL-C	3.40 ± 1.03	2.80 ± 0.79^*	3.56 ± 0.82	2.06 ± 0.38^*	< 0.001
MDA, nmol/ml	4.35 ± 0.75	3.44 ± 0.66^*	4.42 ± 0.81	2.25 ± 0.39^*	< 0.001
Resistin, ng/ml	9.17 ± 1.53	8.11 ± 1.35^*	9.37 ± 1.80	7.28 ± 1.37^*	< 0.001
Adiponectin, μg/ml	19.81 ± 1.95	21.61 ± 1.86^*	19.21 ± 2.10	23.36 ± 2.10^*	< 0.001
TNF-α, pg/ml	9.79 ± 3.42	7.95 ± 2.64^*	10.13 ± 2.90	3.96 ± 1.00^*	< 0.001
FMD, %	3.93 ± 1.29	4.01 ± 1.22	3.72 ± 2.02	6.74 ± 3.78^*	< 0.001

↵* p < 0.001;
↵** p < 0.05 compared to baseline values.
↵† The effect of individual treatments was determined by ANCOVA (final column). TJC: tender joint count; SJC: swollen joint count; VAS: visual analog score; DAS28: disease activity score for 28 joints; other abbreviations as in Table 1.